MORE►
Caris Discovery
Left: Milan Radovich, SVP and Chief Scientific Officer at Caris Life Sciences; Right: Boris L. Zaïtra, Head of Roche Corporate Business Development [Photos: LinkedIn/Roche]
North Texas’ Caris Life Sciences To Collaborate With Genentech on Novel Therapeutic Targets for Cancers
by Sandra Engelland | Dec 17, 2025
Under the terms of the agreement, Caris is eligible to receive upfront and near-term payments of $25 million and is also eligible for up to $1.1 billion of potential research, development, commercial, and net sales payments, as well as potential tiered royalties on net sales of collaboration therapies, the company said.
